Merrifield C Ann's Form 4 filing
Lyra Therapeutics, Inc. (LYRA) · filed May 17, 2022
- Accession no.
- 0000899243-22-018435
- Filed
- May 17, 2022
- Trade date
- May 13-16, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $18.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Merrifield C AnnCIK 0001247224 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 13, 2022 | Common Stock | PPurchaseAcquired | +3,500 | $4.81 | +$16,835 | 7,000 | Direct | |
| May 16, 2022 | Common Stock | PPurchaseAcquired | +328 | $5.00 | +$1,640 | 7,328 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Exhibit 24 - Power of Attorney